You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
GC for Parents - AOS and CP - Information Source
- Thread starter JohnnyCash
- Start date
visaapplicant
Registered Users (C)
Hi Visaapplicant,
I have the same issue as you. I need a letter just like yours above for my mom. Review this post for more details.
http://boards.immigration.com/showthread.php?p=1743929
The issue is I dont know anyone in India. Can you please email me at sellerjax_at_gmail-dot-com please. You have no idea how much I would appreciate this.
I read your post. There have been cases similar to yours in the forum. But I do not know how they managed it.
I have heard about mymaninindia.com providing such services as obtaining documents for a fee. I do not have experience with it but something you can consider. Also call Indian consulate and ask them how they can help. Good luck!
hopegcfast
Registered Users (C)
I-130 document questions
Hi all,
First of all, thanks for all your efforts to help someone like me.
I am very glad that this forum exists.
I am a naturalized citizen through marriage and trying to apply I-130 for my mother who lives out of U.S. So I will have to apply just I-130 now. Right?
However during preparing to I-130, I have a several questions.
They may be very simple to you, but it is very confusing to me.
According to I-130 instruction, I need to answers all questions.
Part B.
#12. Date(s) Marriage(s) Ended
--> I am still married, so do I just put "N/A" in this field? Or just leave blank?
#14b. Did you gain permanent resident status through marriage to a USC...?
--> Since this question is under question #14, I think it belongs to PR alien. However I am, currently, a USC through marriage. It means that I was a PR before a USC.
Do I still have to put "Yes", although I put "N/A" on question #14? Or do I put "No" since I am a USC currently?
Part C.
My mother is widowed. She doesn't get a marriage again after my father died. I am not sure what other people think, but I still think they are still married. So I have questions.
#8. Date and Place of Present Marriage (if married)
--> Do I have to put "N/A"? or put information correponding to my deceased father and widowed mother?
#11. Name(s) of Prior Husband(s)/Wive(s)
--> "None" or my deceased father?
#12. Date(s) Marriage(s) Ended
--> Leave blank, "N/A", or, the date where my father died?
#17. List husband/wife and all children of your relative.
--> Do I have to put my deceased father's information? Or do I have to take my father's information out?
Other question
--> Where should the supporting documents be notarized? Does USCIS accept the ducouments notarized in foreign country (out of U.S.)? Or do I have to get the documents notarized in U.S only?
Thanks for all your help in advance.
Hi all,
First of all, thanks for all your efforts to help someone like me.
I am very glad that this forum exists.
I am a naturalized citizen through marriage and trying to apply I-130 for my mother who lives out of U.S. So I will have to apply just I-130 now. Right?
However during preparing to I-130, I have a several questions.
They may be very simple to you, but it is very confusing to me.
According to I-130 instruction, I need to answers all questions.
Part B.
#12. Date(s) Marriage(s) Ended
--> I am still married, so do I just put "N/A" in this field? Or just leave blank?
#14b. Did you gain permanent resident status through marriage to a USC...?
--> Since this question is under question #14, I think it belongs to PR alien. However I am, currently, a USC through marriage. It means that I was a PR before a USC.
Do I still have to put "Yes", although I put "N/A" on question #14? Or do I put "No" since I am a USC currently?
Part C.
My mother is widowed. She doesn't get a marriage again after my father died. I am not sure what other people think, but I still think they are still married. So I have questions.
#8. Date and Place of Present Marriage (if married)
--> Do I have to put "N/A"? or put information correponding to my deceased father and widowed mother?
#11. Name(s) of Prior Husband(s)/Wive(s)
--> "None" or my deceased father?
#12. Date(s) Marriage(s) Ended
--> Leave blank, "N/A", or, the date where my father died?
#17. List husband/wife and all children of your relative.
--> Do I have to put my deceased father's information? Or do I have to take my father's information out?
Other question
--> Where should the supporting documents be notarized? Does USCIS accept the ducouments notarized in foreign country (out of U.S.)? Or do I have to get the documents notarized in U.S only?
Thanks for all your help in advance.
Last edited by a moderator:
Getting immunization done in India before filing GC here
Hey Folks,
The medical tests for GC in California is pretty expensive therefore I was thinking at least to get my parents some shots before they come here.
My mother is 58 years old and my father is 69 years old. What shots should I ask them to get done before they come here. We can assume that they have no shots taken until now.
Hey Folks,
The medical tests for GC in California is pretty expensive therefore I was thinking at least to get my parents some shots before they come here.
My mother is 58 years old and my father is 69 years old. What shots should I ask them to get done before they come here. We can assume that they have no shots taken until now.
need guidence
Frineds,
First thanks all for this very usefull link.Can u please guide me to right path also.
-My spouse has just got(GC) through (AOS) came to US on B2.Now applying for my parents(AOS).they are on B2 visa in US.
pls adv is it going to create any problem porblem in there case.as I am going to mention in parents (130) that I have alreadyy sponser my spouse through same procedure (AOS).
thanks again for your valuable input.
regards/kab901
Frineds,
First thanks all for this very usefull link.Can u please guide me to right path also.
-My spouse has just got(GC) through (AOS) came to US on B2.Now applying for my parents(AOS).they are on B2 visa in US.
pls adv is it going to create any problem porblem in there case.as I am going to mention in parents (130) that I have alreadyy sponser my spouse through same procedure (AOS).
thanks again for your valuable input.
regards/kab901
Getead, The affidavit must be sworn. It doesn't matter what kind of paper it is on. You could print it out neatly by hand if you don't have a printer. Take it to a local notary or commissioner of oaths and sign it in front of them. Just be sure to tell them you need it sworn. If your uncle is attesting to your mother's DOB then he must swear it out in front of the notary.
Samcal, the immunization schedule is found on the CDC website http://www.cdc.gov/vaccines/recs/schedules/adult-schedule.htm or call 1 800 CDC INFO. At the very least they'll need Tetanus, Diphtheria, Pertussis, Mumps, Measles, Rubella, Varicella (if they haven't had chicken pox), Pneumoccocal and influenza (in season).
Recommended Adult Immunization Schedule, by Vaccine and Age Group
Vaccine: Tetanus, diphtheria, pertussis (Td/Tdap)
Age group: 19-49 years – Dosage: 1 dose Td booster every 10 years, Substitute 1 dose of Tdap for Td
Age group: 50-64 years – Dosage: 1 dose Td booster every 10 years, Substitute 1 dose of Tdap for Td
Age group: greater than or equal to 65 years – Dosage: 1 dose Td booster every 10 years
For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection)
Covered by the Vaccine Injury Compensation Program.
NOTE: These recommendations must be read with the footnotes.
Footnote 1:
Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination. Adults with uncertain histories of a complete primary vaccination series with diphtheria and tetanus toxoid–containing vaccines should begin or complete a primary vaccination series. A primary series for adults is 3 doses; administer the first 2 doses at least 4 weeks apart and the third dose 6–12 months after the second. Administer a booster dose to adults who have completed a primary series and if the last vaccination was received >10 years previously. Tdap or tetanus and diphtheria (Td) vaccine may be used; Tdap should replace a single dose of Td for adults aged <65 years who have not previously received a dose of Tdap (either in the primary series, as a booster, or for wound management). Only one of two Tdap products (Adacel® [sanofi pasteur, Swiftwater, Pennsylvania]) is licensed for use in adults. If the person is pregnant and received the last Td vaccination >10 years previously, administer Td during the second or third trimester; if the person received the last Td vaccination in <10 years, administer Tdap during the immediate postpartum period. A one-time administration of 1-dose of Tdap with an interval as short as 2 years from a previous Td vaccination is recommended for postpartum women, close contacts of infants aged <12 months, and all healthcare workers with direct patient contact. In certain situations, Td can be deferred during pregnancy and Tdap substituted in the immediate postpartum period, or Tdap can be given instead of Td to a pregnant woman after an informed discussion with the woman (see www.cdc.gov/nip/publications/acip-list.htm ). Consult the ACIP statement for recommendations for administering Td as prophylaxis in wound management (www.cdc.gov/mmwr/preview/mmwrhtml/00041645.htm ).
Vaccine: Human papillomavirus (HPV)
Age group: 19-49 years – Dosage: 3 doses (females)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Footnote 2:
Human papillomavirus (HPV) vaccination. HPV vaccination is recommended for all females aged <26 years who have not completed the vaccine series. Ideally, vaccine should be administered before potential exposure to HPV through sexual activity; however, women who are sexually active should still be vaccinated. Sexually active women who have not been infected with any of the HPV vaccine types receive the full benefit of the vaccination. Vaccination is less beneficial for women who have already been infected with one or more of the four HPV vaccine types. A complete series consists of 3 doses. The second dose should be administered 2 months after the first dose; the third dose should be administered 6 months after the first dose. Vaccination is not recommended during pregnancy. If a woman is found to be pregnant after initiating the vaccination series, the remainder of the 3-dose regimen should be delayed until after completion of the pregnancy.
Vaccine: Measles, mumps, rubella (MMR)
Age group: 19-49 years – Dosage: 1 or 2 doses
For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection)
Age group: 50-64 years – Dosage: 1 dose
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: greater than or equal to 65 years – Dosage: 1 dose
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Covered by the Vaccine Injury Compensation Program.
NOTE: These recommendations must be read with the footnotes.
Footnote 3:
Measles, mumps, rubella (MMR) vaccination. Measles component: adults born before 1957 can be considered immune to measles. Adults born during or after 1957 should receive >1 dose of MMR unless they have a medical contraindication, documentation of >1 dose, history of measles based on healthcare provider diagnosis, or laboratory evidence of immunity. A second dose of MMR is recommended for adults who 1) have been recently exposed to measles or in an outbreak setting; 2) have been previously vaccinated with killed measles vaccine; 3) have been vaccinated with an unknown type of measles vaccine during 1963–1967; 4) are students in postsecondary educational institutions; 5) work in a healthcare facility; or 6) plan to travel internationally. Withhold MMR or other measles-containing vaccines from HIV-infected persons with severe immunosuppression. Mumps component: adults born before 1957 can generally be considered immune to mumps. Adults born during or after 1957 should receive 1 dose of MMR unless they have a medical contraindication, history of mumps based on healthcare provider diagnosis, or laboratory evidence of immunity. A second dose of MMR is recommended for adults who 1) are in an age group that is affected during a mumps outbreak; 2) are students in postsecondary educational institutions; 3) work in a healthcare facility; or 4) plan to travel internationally. For unvaccinated healthcare workers born before 1957 who do not have other evidence of mumps immunity, consider giving 1 dose on a routine basis and strongly consider giving a second dose during an outbreak. Rubella component: administer 1 dose of MMR vaccine to women whose rubella vaccination history is unreliable or who lack laboratory evidence of immunity. For women of childbearing age, regardless of birth year, routinely determine rubella immunity and counsel women regarding congenital rubella syndrome. Do not vaccinate women who are pregnant or who might become pregnant within 4 weeks of receiving vaccine. Women who do not have evidence of immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the healthcare facility.
Vaccine: Varicella
Age group: 19-49 years – Dosage: 2 doses (0, 4–8 wks)
For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection)
Age group: 50-64 years – Dosage: 2 doses (0, 4–8 wks)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Covered by the Vaccine Injury Compensation Program.
NOTE: These recommendations must be read with the footnotes.
Footnote 4:
Varicella vaccination. All adults without evidence of immunity to varicella should receive 2 doses of varicella vaccine. Special consideration should be given to those who 1) have close contact with persons at high risk for severe disease (e.g., healthcare workers and family contacts of immunocompromised persons) or 2) are at high risk for exposure or transmission (e.g., teachers of young children; child care employees; residents and staff members of institutional settings, including correctional institutions; college students; military personnel; adolescents and adults living in households with children; non-pregnant women of childbearing age; and international travelers). Evidence of immunity to varicella in adults includes any of the following: 1) documentation of 2 doses of varicella vaccine at least 4 weeks apart; 2) U.S.-born before 1980 (although for healthcare workers and pregnant women, birth before 1980 should not be considered evidence of immunity); 3) history of varicella based on diagnosis or verification of varicella by a healthcare provider (for a patient reporting a history of or presenting with an atypical case, a mild case, or both, healthcare providers should seek either an epidemiologic link with a typical varicella case or evidence of laboratory confirmation, if it was performed at the time of acute disease); 4) history of herpes zoster based on healthcare provider diagnosis; or 5) laboratory evidence of immunity or laboratory confirmation of disease. Do not vaccinate women who are pregnant or might become pregnant within 4 weeks of receiving the vaccine. Assess pregnant women for evidence of varicella immunity. Women who do not have evidence of immunity should receive dose 1 of varicella vaccine upon completion or termination of pregnancy and before discharge from the healthcare facility. Dose 2 should be administered 4–8 weeks after dose 1.
Vaccine: Influenza
Age group: 19-49 years – Dosage: 1 dose annually
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: 50-64 years – Dosage: 1 dose annually
For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection)
Age group: greater than or equal to 65 years – Dosage: 1 dose annually
For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection)
Covered by the Vaccine Injury Compensation Program.
NOTE: These recommendations must be read with the footnotes.
Footnote 5:
5. Influenza vaccination. Medical indications: chronic disorders of the cardiovascular or pulmonary systems, including asthma; chronic metabolic diseases, including diabetes mellitus, renal dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused by medications or HIV); any condition that compromises respiratory function or the handling of respiratory secretions or that can increase the risk of aspiration (e.g., cognitive dysfunction, spinal cord injury, or seizure disorder or other neuromuscular disorder); and pregnancy during the influenza season. No data exist on the risk for severe or complicated influenza disease among persons with asplenia; however, influenza is a risk factor for secondary bacterial infections that can cause severe disease among persons with asplenia. Occupational indications: healthcare workers and employees of long-term–care and assisted living facilities. Other indications: residents of nursing homes and other long-term–care and assisted living facilities; persons likely to transmit influenza to persons at high risk (i.e., in-home household contacts and caregivers of children aged 0–59 months, or persons of all ages with high-risk conditions); and anyone who would like to be vaccinated. Healthy, nonpregnant persons aged 5–49 years without high-risk medical conditions who are not contacts of severely immunocompromised persons in special care units can receive either intranasally administered influenza vaccine (FluMist®) or inactivated vaccine. Other persons should receive the inactivated vaccine.
Vaccine: Pneumococcal (polysaccharide)
Age group: 19-49 years – Dosage: 1–2 doses
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: 50-64 years – Dosage: 1–2 doses
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: greater than or equal to 65 years –1 dose
For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection)
Footnotes 6 and 7:
Footnote 6: Pneumococcal polysaccharide vaccination. Medical indications: chronic disorders of the pulmonary system (excluding asthma); cardiovascular diseases; diabetes mellitus; chronic liver diseases, including liver disease as a result of alcohol abuse (e.g., cirrhosis); chronic renal failure or nephrotic syndrome; functional or anatomic asplenia (e.g., sickle cell disease or splenectomy [if elective splenectomy is planned, vaccinate at least 2 weeks before surgery]); immunosuppressive conditions (e.g., congenital immunodeficiency, HIV infection [vaccinate as close to diagnosis as possible when CD4 cell counts are highest], leukemia, lymphoma, multiple myeloma, Hodgkin disease, generalized malignancy, or organ or bone marrow transplantation); chemotherapy with alkylating agents, antimetabolites, or high-dose, long-term corticosteroids; and cochlear implants. Other indications: Alaska Natives and certain American Indian populations and residents of nursing homes or other long-term–care facilities.
Footnote 7: Revaccination with pneumococcal polysaccharide vaccine. Onetime revaccination after 5 years for persons with chronic renal failure or nephrotic syndrome; functional or anatomic asplenia (e.g., sickle cell disease or splenectomy); immunosuppressive conditions (e.g., congenital immunodeficiency, HIV infection, leukemia, lymphoma, multiple myeloma, Hodgkin disease, generalized malignancy, or organ or bone marrow transplantation); or chemotherapy with alkylating agents, antimetabolites, or high-dose, long-term corticosteroids. For persons aged >65 years, one-time revaccination if they were vaccinated >5 years previously and were aged <65 years at the time of primary vaccination.
Vaccine: Hepatitis A
Age group: 19-49 years – Dosage: 2 doses (0, 6–12 mos, or 0, 6–18 mos)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: 50-64 years – Dosage: 2 doses (0, 6–12 mos, or 0, 6–18 mos)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: greater than or equal to 65 years – Dosage: 2 doses (0, 6–12 mos, or 0, 6–18 mos)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Covered by the Vaccine Injury Compensation Program.
NOTE: These recommendations must be read with the footnotes.
Footnote 8:
Hepatitis A vaccination. Medical indications: persons with chronic liver disease and persons who receive clotting factor concentrates. Behavioral indications: men who have sex with men and persons who use illegal drugs. Occupational indications: persons working with hepatitis A virus (HAV)–infected primates or with HAV in a research laboratory setting. Other indications: persons traveling to or working in countries that have high or intermediate endemicity of hepatitis A (a list of countries is available at www.cdc.gov/travel/diseases.htm ) and any person who would like to obtain immunity. Current vaccines should be administered in a 2-dose schedule at either 0 and 6–12 months, or 0 and 6–18 months. If the combined hepatitis A and hepatitis B vaccine is used, administer 3 doses at 0, 1, and 6 months.
Vaccine: Hepatitis B
Age group: 19-49 years – Dosage: 3 doses (0, 1–2, 4–6 mos)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: 50-64 years – Dosage: 3 doses (0, 1–2, 4–6 mos)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: greater than or equal to 65 years – Dosage: 3 doses (0, 1–2, 4–6 mos)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Covered by the Vaccine Injury Compensation Program.
NOTE: These recommendations must be read with the footnotes.
Footnote 9:
Hepatitis B vaccination. Medical indications: persons with endstage renal disease, including patients receiving hemodialysis; persons seeking evaluation or treatment for a sexually transmitted disease (STD); persons with HIV infection; persons with chronic liver disease; and persons who receive clotting factor concentrates. Occupational indications: healthcare workers and public-safety workers who are exposed to blood or other potentially infectious body fluids. Behavioral indications: sexually active persons who are not in a long-term, mutually monogamous relationship (i.e., persons with >1 sex partner during the previous 6 months); current or recent injection-drug users; and men who have sex with men. Other indications: household contacts and sex partners of persons with chronic hepatitis B virus (HBV) infection; clients and staff members of institutions for persons with developmental disabilities; all clients of STD clinics; international travelers to countries with high or intermediate prevalence of chronic HBV infection (a list of countries is available at www.cdc.gov/travel/diseases.htm); and any adult seeking protection from HBV infection. Settings where hepatitis B vaccination is recommended for all adults: STD treatment facilities; HIV testing and treatment facilities; facilities providing drug-abuse treatment and prevention services; healthcare settings providing services for injection-drug users or men who have sex with men; correctional facilities; end-stage renal disease programs and facilities for chronic hemodialysis patients; and institutions and nonresidential daycare facilities for persons with developmental disabilities. Special formulation indications: for adult patients receiving hemodialysis and other immunocompromised adults, 1 dose of 40 µg/mL (Recombivax HB®) or 2 doses of 20 µg/mL (Engerix-B®).
Vaccine: Meningococcal
Age group: 19-49 years – Dosage: 1 or more doses
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: 50-64 years – Dosage: 1 or more doses
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: greater than or equal to 65 years – Dosage: 1 or more doses
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Footnote 10:
10. Meningococcal vaccination. Medical indications: adults with anatomic or functional asplenia, or terminal complement component deficiencies. Other indications: first-year college students living in dormitories; microbiologists who are routinely exposed to isolates of Neisseria meningitidis; military recruits; and persons who travel to or live in countries in which meningococcal disease is hyperendemic or epidemic (e.g., the “meningitis belt” of sub-Saharan Africa during the dry season [December–June]), particularly if their contact with local populations will be prolonged. Vaccination is required by the government of Saudi Arabia for all travelers to Mecca during the annual Hajj. Meningococcal conjugate vaccine is preferred for adults with any of the preceding indications who are aged <55 years, although meningococcal polysaccharide vaccine (MPSV4) is an acceptable alternative. Revaccination after 5 years might be indicated for adults previously vaccinated with MPSV4 who remain at high risk for infection (e.g., persons residing in areas in which disease is epidemic).
This schedule indicates the recommended age groups and medical indications for routine administration of currently licensed vaccines for persons aged >19 years, as of October 1, 2006. Licensed combination vaccines may be used whenever any components of the combination are indicated and when the vaccine’s other components are not contraindicated. For detailed recommendations on all vaccines, including those used primarily for travelers or that are issued during the year, consult the manufacturers’ package inserts and the complete statements from the Advisory Committee on Immunization Practices (www.cdc.gov/nip/publications/acip-list.htm ).
Report all clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System (VAERS). Reporting forms and instructions on filing a VAERS report are available at www.vaers.hhs.gov or by telephone, 800-822-7967.
Information on how to file a Vaccine Injury Compensation Program claim is available at www.hrsa.gov/vaccinecompensation or by telephone, 800-338-2382. To file a claim for vaccine injury, contact the U.S. Court of Federal Claims, 717 Madison Place, N.W., Washington, D.C. 20005; telephone, 202-357-6400.
Additional information about the vaccines in this schedule and contraindications for vaccination is also available at www.cdc.gov/nip or from the CDC-INFO Contact Center at 800-CDC-INFO (800-232-4636) in English and Spanish, 24 hours a day, 7 days a week.
Recommended Adult Immunization Schedule, by Vaccine and Medical and Other Indications
Ø Indication
Ø Pregnancy
Ø Congenital immunodeficiency, leukemia, (Footnote 11: Selected conditions for which Haemophilus influenzae type b (Hib) vaccine may be used. Hib conjugate vaccines are licensed for children aged 6 weeks–71 months. No efficacy data are available on which to base a recommendation concerning use of Hib vaccine for older children and adults with the chronic conditions associated with an increased risk for Hib disease. However, studies suggest good immunogenicity in patients who have sickle cell disease, leukemia, or HIV infection or who have had splenectomies; administering vaccine to these patients is not contraindicated.) lymphoma, generalized malignancy, cerebrospinal fluid leaks, therapy with alkylating agents, antimetabolites, radiation, or high-dose, long-term corticosteroids
Ø Diabetes, heart disease, chronic pulmonary disease, chronic alcoholism
Ø Asplenia (Footnote 11: Selected conditions for which Haemophilus influenzae type b (Hib) vaccine may be used. Hib conjugate vaccines are licensed for children aged 6 weeks–71 months. No efficacy data are available on which to base a recommendation concerning use of Hib vaccine for older children and adults with the chronic conditions associated with an increased risk for Hib disease. However, studies suggest good immunogenicity in patients who have sickle cell disease, leukemia, or HIV infection or who have had splenectomies; administering vaccine to these patients is not contraindicated.) (including elective splenectomy and terminal complement component deficiencies)
Ø Chronic liver disease, recipients of clotting factor concentrates
Ø Kidney failure, end-stage renal disease, recipients of hemodialysis
Ø Human immunodeficiency virus (HIV) infection Footnote 3: Measles, mumps, rubella (MMR) vaccination. Measles component: adults born before 1957 can be considered immune to measles. Adults born during or after 1957 should receive >1 dose of MMR unless they have a medical contraindication, documentation of >1 dose, history of measles based on healthcare provider diagnosis, or laboratory evidence of immunity. A second dose of MMR is recommended for adults who 1) have been recently exposed to measles or in an outbreak setting; 2) have been previously vaccinated with killed measles vaccine; 3) have been vaccinated with an unknown type of measles vaccine during 1963–1967; 4) are students in postsecondary educational institutions; 5) work in a healthcare facility; or 6) plan to travel internationally. Withhold MMR or other measles-containing vaccines from HIV-infected persons with severe immunosuppression. Mumps component: adults born before 1957 can generally be considered immune to mumps. Adults born during or after 1957 should receive 1 dose of MMR unless they have a medical contraindication, history of mumps based on healthcare provider diagnosis, or laboratory evidence of immunity. A second dose of MMR is recommended for adults who 1) are in an age group that is affected during a mumps outbreak; 2) are students in postsecondary educational institutions; 3) work in a healthcare facility; or 4) plan to travel internationally. For unvaccinated healthcare workers born before 1957 who do not have other evidence of mumps immunity, consider giving 1 dose on a routine basis and strongly consider giving a second dose during an outbreak. Rubella component: administer 1 dose of MMR vaccine to women whose rubella vaccination history is unreliable or who lack laboratory evidence of immunity. For women of childbearing age, regardless of birth year, routinely determine rubella immunity and counsel women regarding congenital rubella syndrome. Do not vaccinate women who are pregnant or who might become pregnant within 4 weeks of receiving vaccine. Women who do not have evidence of immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the healthcare facility), (Footnote 11: Selected conditions for which Haemophilus influenzae type b (Hib) vaccine may be used. Hib conjugate vaccines are licensed for children aged 6 weeks–71 months. No efficacy data are available on which to base a recommendation concerning use of Hib vaccine for older children and adults with the chronic conditions associated with an increased risk for Hib disease. However, studies suggest good immunogenicity in patients who have sickle cell disease, leukemia, or HIV infection or who have had splenectomies; administering vaccine to these patients is not contraindicated.)
Ø Healthcare workers
Vaccine
Tetanus, diphtheria, pertussis (Td/Tdap)1,*
Human papillomavirus (HPV)2
Measles, mumps, rubella (MMR)3,*
Varicella4,*
Influenza5,*
Pneumococcal (polysaccharide)6,7
Hepatitis A8,*
Hepatitis B9,*
Meningococcal10
1 dose Td booster every 10 yrs
Substitute 1 dose of Tdap for Td
3 doses for females through age 26 yrs (0, 2, 6 mos)
1 or 2 doses
2 doses (0, 4–8 wks)
2 doses
1 dose annually
1 dose annually
1 dose annually
1–2 doses
1–2 doses
1–2 doses
2 doses (0, 6–12 mos, or 0, 6–18 mos)
2 doses
2 doses (0, 6–12 mos, or 0, 6–18 mos)
3 doses (0, 1–2, 4–6 mos)
3 doses (0, 1–2, 4–6 mos)
1 dose
1 dose
1 dose
*Covered by the Vaccine Injury Compensation Program. NOTE: These recommendations must be read with the footnotes (see reverse).
For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Contraindicated
Approved by the Advisory Committee on Immunization Practices, the American College of Obstetricians and Gynecologists, the American Academy of Family Physicians, and the American College of Physicians
HHS logo
CDC logo
Department of Health and Human Services
Centers for Disease Control and Prevention
Recommended Adult Immunization Schedule, by Vaccine and Age Group
Vaccine: Tetanus, diphtheria, pertussis (Td/Tdap)
Age group: 19-49 years – Dosage: 1 dose Td booster every 10 years, Substitute 1 dose of Tdap for Td
Age group: 50-64 years – Dosage: 1 dose Td booster every 10 years, Substitute 1 dose of Tdap for Td
Age group: greater than or equal to 65 years – Dosage: 1 dose Td booster every 10 years
For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection)
Covered by the Vaccine Injury Compensation Program.
NOTE: These recommendations must be read with the footnotes.
Footnote 1:
Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination. Adults with uncertain histories of a complete primary vaccination series with diphtheria and tetanus toxoid–containing vaccines should begin or complete a primary vaccination series. A primary series for adults is 3 doses; administer the first 2 doses at least 4 weeks apart and the third dose 6–12 months after the second. Administer a booster dose to adults who have completed a primary series and if the last vaccination was received >10 years previously. Tdap or tetanus and diphtheria (Td) vaccine may be used; Tdap should replace a single dose of Td for adults aged <65 years who have not previously received a dose of Tdap (either in the primary series, as a booster, or for wound management). Only one of two Tdap products (Adacel® [sanofi pasteur, Swiftwater, Pennsylvania]) is licensed for use in adults. If the person is pregnant and received the last Td vaccination >10 years previously, administer Td during the second or third trimester; if the person received the last Td vaccination in <10 years, administer Tdap during the immediate postpartum period. A one-time administration of 1-dose of Tdap with an interval as short as 2 years from a previous Td vaccination is recommended for postpartum women, close contacts of infants aged <12 months, and all healthcare workers with direct patient contact. In certain situations, Td can be deferred during pregnancy and Tdap substituted in the immediate postpartum period, or Tdap can be given instead of Td to a pregnant woman after an informed discussion with the woman (see www.cdc.gov/nip/publications/acip-list.htm ). Consult the ACIP statement for recommendations for administering Td as prophylaxis in wound management (www.cdc.gov/mmwr/preview/mmwrhtml/00041645.htm ).
Vaccine: Human papillomavirus (HPV)
Age group: 19-49 years – Dosage: 3 doses (females)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Footnote 2:
Human papillomavirus (HPV) vaccination. HPV vaccination is recommended for all females aged <26 years who have not completed the vaccine series. Ideally, vaccine should be administered before potential exposure to HPV through sexual activity; however, women who are sexually active should still be vaccinated. Sexually active women who have not been infected with any of the HPV vaccine types receive the full benefit of the vaccination. Vaccination is less beneficial for women who have already been infected with one or more of the four HPV vaccine types. A complete series consists of 3 doses. The second dose should be administered 2 months after the first dose; the third dose should be administered 6 months after the first dose. Vaccination is not recommended during pregnancy. If a woman is found to be pregnant after initiating the vaccination series, the remainder of the 3-dose regimen should be delayed until after completion of the pregnancy.
Vaccine: Measles, mumps, rubella (MMR)
Age group: 19-49 years – Dosage: 1 or 2 doses
For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection)
Age group: 50-64 years – Dosage: 1 dose
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: greater than or equal to 65 years – Dosage: 1 dose
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Covered by the Vaccine Injury Compensation Program.
NOTE: These recommendations must be read with the footnotes.
Footnote 3:
Measles, mumps, rubella (MMR) vaccination. Measles component: adults born before 1957 can be considered immune to measles. Adults born during or after 1957 should receive >1 dose of MMR unless they have a medical contraindication, documentation of >1 dose, history of measles based on healthcare provider diagnosis, or laboratory evidence of immunity. A second dose of MMR is recommended for adults who 1) have been recently exposed to measles or in an outbreak setting; 2) have been previously vaccinated with killed measles vaccine; 3) have been vaccinated with an unknown type of measles vaccine during 1963–1967; 4) are students in postsecondary educational institutions; 5) work in a healthcare facility; or 6) plan to travel internationally. Withhold MMR or other measles-containing vaccines from HIV-infected persons with severe immunosuppression. Mumps component: adults born before 1957 can generally be considered immune to mumps. Adults born during or after 1957 should receive 1 dose of MMR unless they have a medical contraindication, history of mumps based on healthcare provider diagnosis, or laboratory evidence of immunity. A second dose of MMR is recommended for adults who 1) are in an age group that is affected during a mumps outbreak; 2) are students in postsecondary educational institutions; 3) work in a healthcare facility; or 4) plan to travel internationally. For unvaccinated healthcare workers born before 1957 who do not have other evidence of mumps immunity, consider giving 1 dose on a routine basis and strongly consider giving a second dose during an outbreak. Rubella component: administer 1 dose of MMR vaccine to women whose rubella vaccination history is unreliable or who lack laboratory evidence of immunity. For women of childbearing age, regardless of birth year, routinely determine rubella immunity and counsel women regarding congenital rubella syndrome. Do not vaccinate women who are pregnant or who might become pregnant within 4 weeks of receiving vaccine. Women who do not have evidence of immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the healthcare facility.
Vaccine: Varicella
Age group: 19-49 years – Dosage: 2 doses (0, 4–8 wks)
For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection)
Age group: 50-64 years – Dosage: 2 doses (0, 4–8 wks)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Covered by the Vaccine Injury Compensation Program.
NOTE: These recommendations must be read with the footnotes.
Footnote 4:
Varicella vaccination. All adults without evidence of immunity to varicella should receive 2 doses of varicella vaccine. Special consideration should be given to those who 1) have close contact with persons at high risk for severe disease (e.g., healthcare workers and family contacts of immunocompromised persons) or 2) are at high risk for exposure or transmission (e.g., teachers of young children; child care employees; residents and staff members of institutional settings, including correctional institutions; college students; military personnel; adolescents and adults living in households with children; non-pregnant women of childbearing age; and international travelers). Evidence of immunity to varicella in adults includes any of the following: 1) documentation of 2 doses of varicella vaccine at least 4 weeks apart; 2) U.S.-born before 1980 (although for healthcare workers and pregnant women, birth before 1980 should not be considered evidence of immunity); 3) history of varicella based on diagnosis or verification of varicella by a healthcare provider (for a patient reporting a history of or presenting with an atypical case, a mild case, or both, healthcare providers should seek either an epidemiologic link with a typical varicella case or evidence of laboratory confirmation, if it was performed at the time of acute disease); 4) history of herpes zoster based on healthcare provider diagnosis; or 5) laboratory evidence of immunity or laboratory confirmation of disease. Do not vaccinate women who are pregnant or might become pregnant within 4 weeks of receiving the vaccine. Assess pregnant women for evidence of varicella immunity. Women who do not have evidence of immunity should receive dose 1 of varicella vaccine upon completion or termination of pregnancy and before discharge from the healthcare facility. Dose 2 should be administered 4–8 weeks after dose 1.
Vaccine: Influenza
Age group: 19-49 years – Dosage: 1 dose annually
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: 50-64 years – Dosage: 1 dose annually
For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection)
Age group: greater than or equal to 65 years – Dosage: 1 dose annually
For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection)
Covered by the Vaccine Injury Compensation Program.
NOTE: These recommendations must be read with the footnotes.
Footnote 5:
5. Influenza vaccination. Medical indications: chronic disorders of the cardiovascular or pulmonary systems, including asthma; chronic metabolic diseases, including diabetes mellitus, renal dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused by medications or HIV); any condition that compromises respiratory function or the handling of respiratory secretions or that can increase the risk of aspiration (e.g., cognitive dysfunction, spinal cord injury, or seizure disorder or other neuromuscular disorder); and pregnancy during the influenza season. No data exist on the risk for severe or complicated influenza disease among persons with asplenia; however, influenza is a risk factor for secondary bacterial infections that can cause severe disease among persons with asplenia. Occupational indications: healthcare workers and employees of long-term–care and assisted living facilities. Other indications: residents of nursing homes and other long-term–care and assisted living facilities; persons likely to transmit influenza to persons at high risk (i.e., in-home household contacts and caregivers of children aged 0–59 months, or persons of all ages with high-risk conditions); and anyone who would like to be vaccinated. Healthy, nonpregnant persons aged 5–49 years without high-risk medical conditions who are not contacts of severely immunocompromised persons in special care units can receive either intranasally administered influenza vaccine (FluMist®) or inactivated vaccine. Other persons should receive the inactivated vaccine.
Vaccine: Pneumococcal (polysaccharide)
Age group: 19-49 years – Dosage: 1–2 doses
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: 50-64 years – Dosage: 1–2 doses
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: greater than or equal to 65 years –1 dose
For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection)
Footnotes 6 and 7:
Footnote 6: Pneumococcal polysaccharide vaccination. Medical indications: chronic disorders of the pulmonary system (excluding asthma); cardiovascular diseases; diabetes mellitus; chronic liver diseases, including liver disease as a result of alcohol abuse (e.g., cirrhosis); chronic renal failure or nephrotic syndrome; functional or anatomic asplenia (e.g., sickle cell disease or splenectomy [if elective splenectomy is planned, vaccinate at least 2 weeks before surgery]); immunosuppressive conditions (e.g., congenital immunodeficiency, HIV infection [vaccinate as close to diagnosis as possible when CD4 cell counts are highest], leukemia, lymphoma, multiple myeloma, Hodgkin disease, generalized malignancy, or organ or bone marrow transplantation); chemotherapy with alkylating agents, antimetabolites, or high-dose, long-term corticosteroids; and cochlear implants. Other indications: Alaska Natives and certain American Indian populations and residents of nursing homes or other long-term–care facilities.
Footnote 7: Revaccination with pneumococcal polysaccharide vaccine. Onetime revaccination after 5 years for persons with chronic renal failure or nephrotic syndrome; functional or anatomic asplenia (e.g., sickle cell disease or splenectomy); immunosuppressive conditions (e.g., congenital immunodeficiency, HIV infection, leukemia, lymphoma, multiple myeloma, Hodgkin disease, generalized malignancy, or organ or bone marrow transplantation); or chemotherapy with alkylating agents, antimetabolites, or high-dose, long-term corticosteroids. For persons aged >65 years, one-time revaccination if they were vaccinated >5 years previously and were aged <65 years at the time of primary vaccination.
Vaccine: Hepatitis A
Age group: 19-49 years – Dosage: 2 doses (0, 6–12 mos, or 0, 6–18 mos)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: 50-64 years – Dosage: 2 doses (0, 6–12 mos, or 0, 6–18 mos)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: greater than or equal to 65 years – Dosage: 2 doses (0, 6–12 mos, or 0, 6–18 mos)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Covered by the Vaccine Injury Compensation Program.
NOTE: These recommendations must be read with the footnotes.
Footnote 8:
Hepatitis A vaccination. Medical indications: persons with chronic liver disease and persons who receive clotting factor concentrates. Behavioral indications: men who have sex with men and persons who use illegal drugs. Occupational indications: persons working with hepatitis A virus (HAV)–infected primates or with HAV in a research laboratory setting. Other indications: persons traveling to or working in countries that have high or intermediate endemicity of hepatitis A (a list of countries is available at www.cdc.gov/travel/diseases.htm ) and any person who would like to obtain immunity. Current vaccines should be administered in a 2-dose schedule at either 0 and 6–12 months, or 0 and 6–18 months. If the combined hepatitis A and hepatitis B vaccine is used, administer 3 doses at 0, 1, and 6 months.
Vaccine: Hepatitis B
Age group: 19-49 years – Dosage: 3 doses (0, 1–2, 4–6 mos)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: 50-64 years – Dosage: 3 doses (0, 1–2, 4–6 mos)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: greater than or equal to 65 years – Dosage: 3 doses (0, 1–2, 4–6 mos)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Covered by the Vaccine Injury Compensation Program.
NOTE: These recommendations must be read with the footnotes.
Footnote 9:
Hepatitis B vaccination. Medical indications: persons with endstage renal disease, including patients receiving hemodialysis; persons seeking evaluation or treatment for a sexually transmitted disease (STD); persons with HIV infection; persons with chronic liver disease; and persons who receive clotting factor concentrates. Occupational indications: healthcare workers and public-safety workers who are exposed to blood or other potentially infectious body fluids. Behavioral indications: sexually active persons who are not in a long-term, mutually monogamous relationship (i.e., persons with >1 sex partner during the previous 6 months); current or recent injection-drug users; and men who have sex with men. Other indications: household contacts and sex partners of persons with chronic hepatitis B virus (HBV) infection; clients and staff members of institutions for persons with developmental disabilities; all clients of STD clinics; international travelers to countries with high or intermediate prevalence of chronic HBV infection (a list of countries is available at www.cdc.gov/travel/diseases.htm); and any adult seeking protection from HBV infection. Settings where hepatitis B vaccination is recommended for all adults: STD treatment facilities; HIV testing and treatment facilities; facilities providing drug-abuse treatment and prevention services; healthcare settings providing services for injection-drug users or men who have sex with men; correctional facilities; end-stage renal disease programs and facilities for chronic hemodialysis patients; and institutions and nonresidential daycare facilities for persons with developmental disabilities. Special formulation indications: for adult patients receiving hemodialysis and other immunocompromised adults, 1 dose of 40 µg/mL (Recombivax HB®) or 2 doses of 20 µg/mL (Engerix-B®).
Vaccine: Meningococcal
Age group: 19-49 years – Dosage: 1 or more doses
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: 50-64 years – Dosage: 1 or more doses
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Age group: greater than or equal to 65 years – Dosage: 1 or more doses
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Footnote 10:
10. Meningococcal vaccination. Medical indications: adults with anatomic or functional asplenia, or terminal complement component deficiencies. Other indications: first-year college students living in dormitories; microbiologists who are routinely exposed to isolates of Neisseria meningitidis; military recruits; and persons who travel to or live in countries in which meningococcal disease is hyperendemic or epidemic (e.g., the “meningitis belt” of sub-Saharan Africa during the dry season [December–June]), particularly if their contact with local populations will be prolonged. Vaccination is required by the government of Saudi Arabia for all travelers to Mecca during the annual Hajj. Meningococcal conjugate vaccine is preferred for adults with any of the preceding indications who are aged <55 years, although meningococcal polysaccharide vaccine (MPSV4) is an acceptable alternative. Revaccination after 5 years might be indicated for adults previously vaccinated with MPSV4 who remain at high risk for infection (e.g., persons residing in areas in which disease is epidemic).
This schedule indicates the recommended age groups and medical indications for routine administration of currently licensed vaccines for persons aged >19 years, as of October 1, 2006. Licensed combination vaccines may be used whenever any components of the combination are indicated and when the vaccine’s other components are not contraindicated. For detailed recommendations on all vaccines, including those used primarily for travelers or that are issued during the year, consult the manufacturers’ package inserts and the complete statements from the Advisory Committee on Immunization Practices (www.cdc.gov/nip/publications/acip-list.htm ).
Report all clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System (VAERS). Reporting forms and instructions on filing a VAERS report are available at www.vaers.hhs.gov or by telephone, 800-822-7967.
Information on how to file a Vaccine Injury Compensation Program claim is available at www.hrsa.gov/vaccinecompensation or by telephone, 800-338-2382. To file a claim for vaccine injury, contact the U.S. Court of Federal Claims, 717 Madison Place, N.W., Washington, D.C. 20005; telephone, 202-357-6400.
Additional information about the vaccines in this schedule and contraindications for vaccination is also available at www.cdc.gov/nip or from the CDC-INFO Contact Center at 800-CDC-INFO (800-232-4636) in English and Spanish, 24 hours a day, 7 days a week.
Recommended Adult Immunization Schedule, by Vaccine and Medical and Other Indications
Ø Indication
Ø Pregnancy
Ø Congenital immunodeficiency, leukemia, (Footnote 11: Selected conditions for which Haemophilus influenzae type b (Hib) vaccine may be used. Hib conjugate vaccines are licensed for children aged 6 weeks–71 months. No efficacy data are available on which to base a recommendation concerning use of Hib vaccine for older children and adults with the chronic conditions associated with an increased risk for Hib disease. However, studies suggest good immunogenicity in patients who have sickle cell disease, leukemia, or HIV infection or who have had splenectomies; administering vaccine to these patients is not contraindicated.) lymphoma, generalized malignancy, cerebrospinal fluid leaks, therapy with alkylating agents, antimetabolites, radiation, or high-dose, long-term corticosteroids
Ø Diabetes, heart disease, chronic pulmonary disease, chronic alcoholism
Ø Asplenia (Footnote 11: Selected conditions for which Haemophilus influenzae type b (Hib) vaccine may be used. Hib conjugate vaccines are licensed for children aged 6 weeks–71 months. No efficacy data are available on which to base a recommendation concerning use of Hib vaccine for older children and adults with the chronic conditions associated with an increased risk for Hib disease. However, studies suggest good immunogenicity in patients who have sickle cell disease, leukemia, or HIV infection or who have had splenectomies; administering vaccine to these patients is not contraindicated.) (including elective splenectomy and terminal complement component deficiencies)
Ø Chronic liver disease, recipients of clotting factor concentrates
Ø Kidney failure, end-stage renal disease, recipients of hemodialysis
Ø Human immunodeficiency virus (HIV) infection Footnote 3: Measles, mumps, rubella (MMR) vaccination. Measles component: adults born before 1957 can be considered immune to measles. Adults born during or after 1957 should receive >1 dose of MMR unless they have a medical contraindication, documentation of >1 dose, history of measles based on healthcare provider diagnosis, or laboratory evidence of immunity. A second dose of MMR is recommended for adults who 1) have been recently exposed to measles or in an outbreak setting; 2) have been previously vaccinated with killed measles vaccine; 3) have been vaccinated with an unknown type of measles vaccine during 1963–1967; 4) are students in postsecondary educational institutions; 5) work in a healthcare facility; or 6) plan to travel internationally. Withhold MMR or other measles-containing vaccines from HIV-infected persons with severe immunosuppression. Mumps component: adults born before 1957 can generally be considered immune to mumps. Adults born during or after 1957 should receive 1 dose of MMR unless they have a medical contraindication, history of mumps based on healthcare provider diagnosis, or laboratory evidence of immunity. A second dose of MMR is recommended for adults who 1) are in an age group that is affected during a mumps outbreak; 2) are students in postsecondary educational institutions; 3) work in a healthcare facility; or 4) plan to travel internationally. For unvaccinated healthcare workers born before 1957 who do not have other evidence of mumps immunity, consider giving 1 dose on a routine basis and strongly consider giving a second dose during an outbreak. Rubella component: administer 1 dose of MMR vaccine to women whose rubella vaccination history is unreliable or who lack laboratory evidence of immunity. For women of childbearing age, regardless of birth year, routinely determine rubella immunity and counsel women regarding congenital rubella syndrome. Do not vaccinate women who are pregnant or who might become pregnant within 4 weeks of receiving vaccine. Women who do not have evidence of immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the healthcare facility), (Footnote 11: Selected conditions for which Haemophilus influenzae type b (Hib) vaccine may be used. Hib conjugate vaccines are licensed for children aged 6 weeks–71 months. No efficacy data are available on which to base a recommendation concerning use of Hib vaccine for older children and adults with the chronic conditions associated with an increased risk for Hib disease. However, studies suggest good immunogenicity in patients who have sickle cell disease, leukemia, or HIV infection or who have had splenectomies; administering vaccine to these patients is not contraindicated.)
Ø Healthcare workers
Vaccine
Tetanus, diphtheria, pertussis (Td/Tdap)1,*
Human papillomavirus (HPV)2
Measles, mumps, rubella (MMR)3,*
Varicella4,*
Influenza5,*
Pneumococcal (polysaccharide)6,7
Hepatitis A8,*
Hepatitis B9,*
Meningococcal10
1 dose Td booster every 10 yrs
Substitute 1 dose of Tdap for Td
3 doses for females through age 26 yrs (0, 2, 6 mos)
1 or 2 doses
2 doses (0, 4–8 wks)
2 doses
1 dose annually
1 dose annually
1 dose annually
1–2 doses
1–2 doses
1–2 doses
2 doses (0, 6–12 mos, or 0, 6–18 mos)
2 doses
2 doses (0, 6–12 mos, or 0, 6–18 mos)
3 doses (0, 1–2, 4–6 mos)
3 doses (0, 1–2, 4–6 mos)
1 dose
1 dose
1 dose
*Covered by the Vaccine Injury Compensation Program. NOTE: These recommendations must be read with the footnotes (see reverse).
For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection)
Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
Contraindicated
Approved by the Advisory Committee on Immunization Practices, the American College of Obstetricians and Gynecologists, the American Academy of Family Physicians, and the American College of Physicians
HHS logo
CDC logo
Department of Health and Human Services
Centers for Disease Control and Prevention
Hi,
My parents have got their interviews 2 days apart in Chennai Consulate. My mom cannot speak English and she has problems standing or walking for long duration due to a surgery. Can I accompany her to the interview assisting her to get to the interview counter and help through the process ? If I take my US passport, will they let me accompany her ?
I sent an email to the consulate trying to find out if I can reschedule both to the same day but they haven't replied. Is this common that chennai office ignores/doesn't reply to emails ?
Any help is appreciated. Thanks.
ONE person is allowed to accompany the beneficiary. I wouldn't change the date of the interview since rescheduling could take up to 6 months or more and there is no guarantee that they will schedule them together.
No problem.Hi all,
First of all, thanks for all your efforts to help someone like me.
I am very glad that this forum exists.
I am a naturalized citizen through marriage and trying to apply I-130 for my mother who lives out of U.S. So I will have to apply just I-130 now. Right?YES
However during preparing to I-130, I have a several questions.
They may be very simple to you, but it is very confusing to me.
According to I-130 instruction, I need to answers all questions.
JUST ANSWER TO THE BEST OF YOUR ABILITY.
Part B.
#12. Date(s) Marriage(s) Ended
--> I am still married, so do I just put "N/A" in this field? Or just leave blank?
BLANK
#14b. Did you gain permanent resident status through marriage to a USC...?
--> Since this question is under question #14, I think it belongs to PR alien. However I am, currently, a USC through marriage. It means that I was a PR before a USC.
Do I still have to put "Yes", although I put "N/A" on question #14? Or do I put "No" since I am a USC currently?N/A. I AM A US CITIZEN.
Part C.
My mother is widowed. She doesn't get a marriage again after my father died. I am not sure what other people think, but I still think they are still married. So I have questions.
#8. Date and Place of Present Marriage (if married)
--> Do I have to put "N/A"? or put information correponding to my deceased father and widowed mother?N/A WIDOWED
#11. Name(s) of Prior Husband(s)/Wive(s)
--> "None" or my deceased father?FATHER'S NAME AND DECEASED
#12. Date(s) Marriage(s) Ended
--> Leave blank, "N/A", or, the date where my father died?LEAVE BLANK OR N/A
#17. List husband/wife and all children of your relative.
--> Do I have to put my deceased father's information? Or do I have to take my father's information out?PUT FATHER'S INFO IN AND "DECEASED" IN BRACKETS
Other question
--> Where should the supporting documents be notarized?NOTARY PUBLIC or COMMISSIONER FOR TAKING OATHS Does USCIS accept the ducouments notarized in foreign country (out of U.S.)? YESOr do I have to get the documents notarized in U.S only?NO
Thanks for all your help in advance.
The sooner you submit the request, the sooner you can get the documents back.Hello All!
I petitioned my parents (Manila Embassy) all went well and they arrived here safely. Just found out yesterday from them that thier original documets (birth cert, marriage cert and my birth cert.)were ,mailed back to them along with their Visa in a sealed envelop . It strickly says do not open... Upon the arrival at the port of Entry (Detroit , MI) they open the package and notice that the original documents were in there . My mom asked the officer if she can have them back and said they will keep them along with the other papers...
My confusion is is that normal that they keep all original doc.?YES, UNLESS YOU REQUEST THE RETURN OF THE ORIGINAL DOCUMENTS AT THE INTERVIEW. I called the 1800 number of USCIS customer service and was advised to submit a form called G-884... Is that correct.YES. G-884 IS FOR RETURN OF ORIGINAL DOCUMENTS. Please advice before i file... thank you.
Abby
Is there a backlog due to the rush before fee increase?
I mailed the I130/I485 concurrent filing at the end of July by priority mail to Chicago Lockbox. The mail has arrived there for 2 and half weeks, but there is no receipt and no check was cashed. I am starting to wonder whether there will be a backlog due to people rushing to file due to the fee increase deadline.
Is there a tracking thread so I can know the current processing time?
Thanks!
I mailed the I130/I485 concurrent filing at the end of July by priority mail to Chicago Lockbox. The mail has arrived there for 2 and half weeks, but there is no receipt and no check was cashed. I am starting to wonder whether there will be a backlog due to people rushing to file due to the fee increase deadline.
Is there a tracking thread so I can know the current processing time?
Thanks!
You Need To Be Entered Into The System First
I don't think that there is a thread or any way to track an application before it is entered into the system. After your application has been processed then it can easily be tracked. Hang in there, things are always slower in the summertime and there may be a backlog due to fears over immigration reform and the fee increase. It shouldn't be too much longer now. In the meantime, check once a week or so. Try not to stress about it.
I don't think that there is a thread or any way to track an application before it is entered into the system. After your application has been processed then it can easily be tracked. Hang in there, things are always slower in the summertime and there may be a backlog due to fears over immigration reform and the fee increase. It shouldn't be too much longer now. In the meantime, check once a week or so. Try not to stress about it.
No Receipt either for us!
I sent I130/485 together to Chicago Lockbox on July 23rd. I didn't get any receipt so far.
However, I received a notice for Finger Prints scheduled for August 31st.
I sent I130/485 together to Chicago Lockbox on July 23rd. I didn't get any receipt so far.
However, I received a notice for Finger Prints scheduled for August 31st.
I mailed the I130/I485 concurrent filing at the end of July by priority mail to Chicago Lockbox. The mail has arrived there for 2 and half weeks, but there is no receipt and no check was cashed. I am starting to wonder whether there will be a backlog due to people rushing to file due to the fee increase deadline.
Is there a tracking thread so I can know the current processing time?
Thanks!
need adv
Guys,
I despreatly need your help.kindly clear this difficult question for me.thanks alot for taking time to read this question
immigration scenario
I am filling AOS for my parents and my wife (AOS) already approved)
-in forms (I-765,I-485, i-131, (do I need to put my name where it say"if someone emlse prepare this form.pls put your name.( As I am filling this form for my parents.)
-I am filling AOS for my parents(mother and father) togather .I have already filled AOS(approved) for my wife. in form 1-130 section D what should I put in
Section D.1
If seperate petitions are also being submitted for other relatives, give names of each and relationship. ( should i put my mother name in father 1-130 and vice versa)
Section D.2
Have you ever before filed a petition for this or any other alien?
(should i put my wife name only in my father and mother 1-130)
Guys,
I despreatly need your help.kindly clear this difficult question for me.thanks alot for taking time to read this question
immigration scenario
I am filling AOS for my parents and my wife (AOS) already approved)
-in forms (I-765,I-485, i-131, (do I need to put my name where it say"if someone emlse prepare this form.pls put your name.( As I am filling this form for my parents.)
-I am filling AOS for my parents(mother and father) togather .I have already filled AOS(approved) for my wife. in form 1-130 section D what should I put in
Section D.1
If seperate petitions are also being submitted for other relatives, give names of each and relationship. ( should i put my mother name in father 1-130 and vice versa)
Section D.2
Have you ever before filed a petition for this or any other alien?
(should i put my wife name only in my father and mother 1-130)
visaapplicant
Registered Users (C)
Answers to your questions are in bold font
Guys,
I despreatly need your help.kindly clear this difficult question for me.thanks alot for taking time to read this question
immigration scenario
I am filling AOS for my parents and my wife (AOS) already approved)
-in forms (I-765,I-485, i-131, (do I need to put my name where it say"if someone emlse prepare this form.pls put your name.( As I am filling this form for my parents.)
Your parents will sign these forms. If they are comfortable with the information you filled, there is no need to put your name.
Even if you put your name, it should not matter.
-I am filling AOS for my parents(mother and father) togather .I have already filled AOS(approved) for my wife. in form 1-130 section D what should I put in
Section D.1
If seperate petitions are also being submitted for other relatives, give names of each and relationship. ( should i put my mother name in father 1-130 and vice versa)
Yes, thats what I did.
Section D.2
Have you ever before filed a petition for this or any other alien?
(should i put my wife name only in my father and mother 1-130)
Yes.
Answers to your questions are in bold font
visaapplicant,
first of all thanks a lot for taking time reply my queries.can u pls also guide me for fees.
-i need to make a one check on 1010$.which include (930+80=1010$).
-Do i need to make only one check 1010 or seprate check for 930 and 80.
-I am fliing EAD,AP with 485.just want to clear this (1010$) include EAD and AP fees also ( Do i need to pay saperatly for EAD and AP. or one check on 1010$ per application should e enough.)
thanks for your guidence.
regards/
Strange Situation
Hi,
I had applied for GC for both of my parents in April 2007. My mother received the card in July.
My father received 485 approval notice in July. Then we got a letter stating that his photos were not acceptable and he had to take biometrics again. It'll been 3 weeks since he got his photos re-taken. However there is no sign of a card.
Also his case status has changed from approved to :
"On May 2007 we transferred your case to CSC ....".
Have anyone been through such a situation ? Is his approval valid ? What can we do if his card doesn't arrive soon ?
Thanks.
Hi,
I had applied for GC for both of my parents in April 2007. My mother received the card in July.
My father received 485 approval notice in July. Then we got a letter stating that his photos were not acceptable and he had to take biometrics again. It'll been 3 weeks since he got his photos re-taken. However there is no sign of a card.
Also his case status has changed from approved to :
"On May 2007 we transferred your case to CSC ....".
Have anyone been through such a situation ? Is his approval valid ? What can we do if his card doesn't arrive soon ?
Thanks.
PraetorianXI
Banned
-i need to make a one check on 1010$.which include (930+80=1010$).
-Do i need to make only one check 1010 or seprate check for 930 and 80.
-I am fliing EAD,AP with 485.just want to clear this (1010$) include EAD and AP fees also ( Do i need to pay saperatly for EAD and AP. or one check on 1010$ per application should e enough.)
Just make 1 check for $ 1,010.
And yes, that fee includes AP and EAD.